Miscellaneous
CME Available: https://auau.auanet.org/node/33900 At the conclusion of this course, participants will be able to: 1. Identify the active agents and their mechanism of action in the management of nmCRPC and mCRPC 2. Describe sequencing and indications for active treatment with approved agents in the management of nmCRPC 3. Analyze the evidence and outcomes on the treatment of MO and M1 CRPC as outlined in the newly updated AUA CRPC guidelines 4. Improve diagnostic and therapeutic decision making processes by illustrating the application of these guidelines in urological practice 5. Analyze breakthrough treatments in the management of advanced and metastatic hormone naïve prostate cancer ACKNOWLEDGEMENTS Independent educational grant support provided by: Amgen Astellas AstraZeneca Bristol-Myers Squibb Exact Sciences Corporation Janssen Biotech, Inc. Administered by Janssen Scientific Affairs, LLC Merck Pfizer, Inc. Sanofi Genzyme